SG11201405755QA - Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate - Google Patents
Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarateInfo
- Publication number
- SG11201405755QA SG11201405755QA SG11201405755QA SG11201405755QA SG11201405755QA SG 11201405755Q A SG11201405755Q A SG 11201405755QA SG 11201405755Q A SG11201405755Q A SG 11201405755QA SG 11201405755Q A SG11201405755Q A SG 11201405755QA SG 11201405755Q A SG11201405755Q A SG 11201405755QA
- Authority
- SG
- Singapore
- Prior art keywords
- laquinimod
- treatment
- combination
- multiple sclerosis
- dimethyl fumarate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Exchange Systems With Centralized Control (AREA)
- Liquid Crystal Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261616337P | 2012-03-27 | 2012-03-27 | |
| US13/800,047 US20130259856A1 (en) | 2012-03-27 | 2013-03-13 | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| PCT/US2013/033885 WO2013148690A1 (en) | 2012-03-27 | 2013-03-26 | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201405755QA true SG11201405755QA (en) | 2014-10-30 |
Family
ID=49235339
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201607976WA SG10201607976WA (en) | 2012-03-27 | 2013-03-26 | Treatment Of Multiple Sclerosis With Combination of Laquinimod And Dimethyl Fumarate |
| SG11201405755QA SG11201405755QA (en) | 2012-03-27 | 2013-03-26 | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201607976WA SG10201607976WA (en) | 2012-03-27 | 2013-03-26 | Treatment Of Multiple Sclerosis With Combination of Laquinimod And Dimethyl Fumarate |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US20130259856A1 (pt) |
| EP (1) | EP2830623A4 (pt) |
| JP (2) | JP2015512406A (pt) |
| KR (1) | KR20150003765A (pt) |
| CN (2) | CN104470520A (pt) |
| AR (1) | AR090491A1 (pt) |
| AU (2) | AU2013239850A1 (pt) |
| CA (1) | CA2868259A1 (pt) |
| EA (1) | EA201491773A1 (pt) |
| HK (1) | HK1205941A1 (pt) |
| IL (1) | IL234687A0 (pt) |
| MX (1) | MX2014011616A (pt) |
| SG (2) | SG10201607976WA (pt) |
| TW (1) | TW201343164A (pt) |
| UY (1) | UY34720A (pt) |
| WO (1) | WO2013148690A1 (pt) |
| ZA (1) | ZA201407722B (pt) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2334378T3 (pl) | 2008-08-19 | 2014-09-30 | Xenoport Inc | Proleki wodorofumaranu metylu, ich kompozycje farmaceutyczne i sposoby zastosowania |
| EP2766020A4 (en) | 2011-10-12 | 2015-04-01 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| KR20140138694A (ko) | 2012-02-03 | 2014-12-04 | 테바 파마슈티컬 인더스트리즈 리미티드 | 최선의 항-TNFα 요법에 실패한 크론병 환자를 치료하기 위한 라퀴니모드의 용도 |
| JP6215238B2 (ja) | 2012-02-16 | 2017-10-18 | テバ ファーマシューティカル インダストリーズ リミティド | Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| EP2692343A1 (en) * | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| US10945984B2 (en) | 2012-08-22 | 2021-03-16 | Arbor Pharmaceuticals, Llc | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| JP2015526477A (ja) | 2012-08-22 | 2015-09-10 | ゼノポート，インコーポレイティド | メチル水素フマレートの経口剤形およびそのプロドラッグ |
| MX2015005632A (es) | 2012-11-07 | 2016-02-05 | Teva Pharma | Sales de amina de laquinimod. |
| BR112015021602A2 (pt) | 2013-03-14 | 2017-07-18 | Teva Pharma | cristais de laquinimod de sódio e processo melhorado para a fabricação dos mesmos |
| US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
| WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
| WO2014205392A1 (en) | 2013-06-21 | 2014-12-24 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| US9416096B2 (en) | 2013-09-06 | 2016-08-16 | Xenoport, Inc. | Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use |
| EP3110408B1 (en) | 2014-02-28 | 2019-01-16 | Banner Life Sciences LLC | Controlled release enteric soft capsules of fumarate esters |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| AU2015253330A1 (en) | 2014-04-29 | 2016-12-01 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
| MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
| GB2540163A (en) * | 2015-07-07 | 2017-01-11 | Univ London Queen Mary | Combination therapy for treating multiple sclerosis |
| WO2017120355A1 (en) * | 2016-01-06 | 2017-07-13 | Teva Pharmaceutical Industries Ltd. | Dihydroquinolines and uses thereof |
| US11903918B2 (en) | 2020-01-10 | 2024-02-20 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| WO2007006308A1 (en) * | 2005-07-07 | 2007-01-18 | Aditech Pharma Ab | Novel glucopyranose esters and glucofuranose esters of alkyl- fu marates and their pharmaceutical use |
| WO2007047863A2 (en) | 2005-10-19 | 2007-04-26 | Teva Pharmaceutical Industries, Ltd. | Crystals of laquinimod sodium, and process for the manufacture thereof |
| KR101495327B1 (ko) * | 2006-06-12 | 2015-02-24 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| ES2916604T1 (es) | 2007-02-08 | 2022-07-04 | Biogen Ma Inc | Ensayos de detección de nrf2 y métodos y composiciones relacionados |
| ES2599227T3 (es) * | 2007-02-08 | 2017-01-31 | Biogen Ma Inc. | Neuroprotección en enfermedades desmielinizantes |
| US20100260755A1 (en) * | 2009-04-09 | 2010-10-14 | Medicinova, Inc. | Ibudilast and immunomodulators combination |
| JP2012525385A (ja) * | 2009-04-29 | 2012-10-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 神経変性および神経炎症の治療 |
| AU2010260455A1 (en) | 2009-06-19 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| RS54551B1 (en) * | 2010-02-12 | 2016-06-30 | Biogen Ma Inc. | NEUROPROTECTION IN DEMYELINING DISEASES |
| US9412161B2 (en) * | 2011-01-25 | 2016-08-09 | Novartis Ag | Systems and methods for medical use of motion imaging and capture |
| TW201347762A (zh) * | 2012-05-02 | 2013-12-01 | Teva Pharma | 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途 |
-
2013
- 2013-03-13 US US13/800,047 patent/US20130259856A1/en not_active Abandoned
- 2013-03-25 AR ARP130100966 patent/AR090491A1/es unknown
- 2013-03-25 TW TW102110549A patent/TW201343164A/zh unknown
- 2013-03-26 EP EP13768294.4A patent/EP2830623A4/en not_active Withdrawn
- 2013-03-26 KR KR20147030064A patent/KR20150003765A/ko not_active Application Discontinuation
- 2013-03-26 AU AU2013239850A patent/AU2013239850A1/en not_active Abandoned
- 2013-03-26 CA CA 2868259 patent/CA2868259A1/en not_active Abandoned
- 2013-03-26 EA EA201491773A patent/EA201491773A1/ru unknown
- 2013-03-26 CN CN201380016933.3A patent/CN104470520A/zh active Pending
- 2013-03-26 CN CN201610252021.1A patent/CN105853422A/zh active Pending
- 2013-03-26 SG SG10201607976WA patent/SG10201607976WA/en unknown
- 2013-03-26 WO PCT/US2013/033885 patent/WO2013148690A1/en active Application Filing
- 2013-03-26 MX MX2014011616A patent/MX2014011616A/es unknown
- 2013-03-26 JP JP2015503465A patent/JP2015512406A/ja not_active Withdrawn
- 2013-03-26 SG SG11201405755QA patent/SG11201405755QA/en unknown
- 2013-04-02 UY UY34720A patent/UY34720A/es not_active Application Discontinuation
-
2014
- 2014-09-16 IL IL234687A patent/IL234687A0/en unknown
- 2014-10-23 ZA ZA2014/07722A patent/ZA201407722B/en unknown
-
2015
- 2015-01-05 US US14/589,684 patent/US20150119420A1/en not_active Abandoned
- 2015-07-09 HK HK15106555.7A patent/HK1205941A1/xx unknown
- 2015-09-14 US US14/853,826 patent/US20160000774A1/en not_active Abandoned
-
2017
- 2017-04-24 US US15/495,406 patent/US20170224675A1/en not_active Abandoned
- 2017-05-26 JP JP2017104051A patent/JP2017200927A/ja not_active Withdrawn
- 2017-07-27 US US15/662,165 patent/US20170319570A1/en not_active Abandoned
- 2017-11-03 US US15/803,017 patent/US20180050031A1/en not_active Abandoned
-
2018
- 2018-01-04 AU AU2018200065A patent/AU2018200065A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017200927A (ja) | 2017-11-09 |
| MX2014011616A (es) | 2014-10-17 |
| TW201343164A (zh) | 2013-11-01 |
| HK1205941A1 (en) | 2015-12-31 |
| US20130259856A1 (en) | 2013-10-03 |
| US20160000774A1 (en) | 2016-01-07 |
| JP2015512406A (ja) | 2015-04-27 |
| EP2830623A1 (en) | 2015-02-04 |
| KR20150003765A (ko) | 2015-01-09 |
| CN105853422A (zh) | 2016-08-17 |
| US20180050031A1 (en) | 2018-02-22 |
| SG10201607976WA (en) | 2016-11-29 |
| EP2830623A4 (en) | 2015-09-02 |
| AR090491A1 (es) | 2014-11-19 |
| US20170319570A1 (en) | 2017-11-09 |
| UY34720A (es) | 2013-10-31 |
| WO2013148690A1 (en) | 2013-10-03 |
| ZA201407722B (en) | 2016-06-29 |
| AU2013239850A1 (en) | 2014-11-06 |
| US20170224675A1 (en) | 2017-08-10 |
| EA201491773A1 (ru) | 2015-02-27 |
| IL234687A0 (en) | 2014-11-30 |
| AU2018200065A1 (en) | 2018-02-01 |
| CA2868259A1 (en) | 2013-10-03 |
| US20150119420A1 (en) | 2015-04-30 |
| CN104470520A (zh) | 2015-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1205941A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate | |
| HK1199820A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fingolimod | |
| IL251397A0 (en) | Treatment of multiple sclerosis by administering a combination of laquinimod and glatiramer acetate | |
| ZA201502503B (en) | Hppd variants and methods of use | |
| IL252547A0 (en) | Treatment of multiple sclerosis using laquinimod | |
| ZA201401217B (en) | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta | |
| EP2912178A4 (en) | SUPER AMPLIFIER AND METHOD FOR USE THEREOF | |
| HK1209672A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fampridine | |
| HK1218254A1 (zh) | 用拉喹莫德治療多發性硬化症 | |
| EP2852397A4 (en) | HUWENTOXIN IV VARIANTS AND METHODS OF USE | |
| ZA201408055B (en) | Compositions and methods for the treatment of local pain | |
| HK1217688A1 (zh) | -氯- 苯基- -茚- -酮及其用途 | |
| GB201103293D0 (en) | Treatment and prevention of malaria | |
| ZA201408062B (en) | Compositions and methods for the treatment of multiple sclerosis | |
| HK1223855A1 (zh) | 拉喹莫德和氟吡汀組合物用於治療多發性硬化症 | |
| ZA201408128B (en) | Etract of greyia radlkoferi and use thereof | |
| HK1227691A1 (zh) | 利用拉喹莫德和特立氟胺的組合來治療多發性硬化症 | |
| ME03635B (me) | 6-hlor0-3-(fenil-d5)-inden-1-on i njegova upotreba |